


Situation of biosimilar candidates whose originator medicine is estimated to lose market exclusivity before 2030



At each stage, the total number of biosimilar candidates is indicated
For more information, see [methodological note](#)

*Active ingredient for which there is already a biosimilar on the market

Centers participating in clinical trials of biosimilars included in the horizon scanning



Medical centers with active clinical trials

Active ingredient	Medical centers
Pembrolizumab	> Complejo Hospitalario Universitario de Ourense (Ourense) > Hospital Quirónsalud Málaga (Málaga) > Hospital Universitario y Politécnico la Fe (Valencia) > Clínica Universidad de Navarra (Navarra) > Hospital Universitario Fundación Jiménez Díaz (Madrid) > Hospital Clínico Universitario de Valladolid (Valladolid) > Complejo Hospitalario Universitario de Santiago (Coruña) > Hospital Universitario Severo Ochoa (Madrid) > Centro Oncológico de Galicia (Coruña) > Hospital Universitario Reina Sofía (Córdoba) > Hospital Arnau de Vilanova de Valencia (Valencia)
Nivolumab	> Hospital HLA Jerez Puerta del Sur (Cádiz) > Hospital Universitari Vall d'Hebron (Barcelona) > Hospital Universitario Virgen de la Macarena (Sevilla) > Hospital General Universitario de Valencia (Valencia) > Hospital San Pedro de Alcántara (Cáceres) > Hospital Universitario Regional de Málaga (Málaga) > Hospital de la Santa Creu i Sant Pau (Barcelona) > Hospital MD Anderson Cancer Center (Madrid) > Institut Català D'Oncologia (Barcelona) > Hospital Clínico Universitario Virgen de la Arrixaca (Murcia)